As a brief background, JAVELIN Bladder 100 is a randomized phase III trial evaluating the use of maintenance immune checkpoint inhibitor avelumab in patients with unresectable locally advanced or ...

Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults. A table of NHS England interim treatment regimens gives possible alternative treatment ...

A total of 805 patients received induction; 499 were randomly assigned to avelumab (n = 249) or continued chemotherapy (n = 250). Median OS was 10.4 months (95% CI, 9.1 to 12.0 months) versus 10.9 ...

Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance.

It agreed that, in the comparison with tivozanib, survival estimates for avelumab plus axitinib in the model should be based on trial data rather than on network meta-analyses. It recognised that ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Another year brings another negative avelumab (Bavencio) trial in ovarian cancer, and more experts are left scratching ...

The MMRD cohort met the predefined primary end point of four ORs after accrual of only 17 patients; of 15 patients who initiated avelumab, four exhibited OR (one complete response, three partial ...

A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1–positive tumors (63.2%), the median ...

Back to Healio A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS. The JAVELIN ...

The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug. Avelumab was granted ...

The structural basis of the anti-PD-L1 antibody blockade was further analyzed by structural superposition of the hPD-1/hPD-Ll complex (PDB: 4ZQK) and the avelumab-scFv/hPD-L1 complex. The avelumab ...